The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease

Anxiety and Depression

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Prog Neuropsychopharmacol Biol Psychiatry.

Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T

doi: 10.1016/

RECOMMENDED

Parkinson’s Disease

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Mov Disord.

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group

doi: 10.1002/mds.27492.

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease

Mov Disord.

Löhle M, Mangone G, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Corvol JC, Storch A

doi: 10.1002/mds.27466.

Parkinson’s Disease

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study

Lancet Neurol.

Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M

doi: 10.1016/S1474-4422

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Brain Neurology Journ.

Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE

doi: 10.1093/brain/awx146.

Anxiety and Depression

Resting frontal EEG asymmetry in adolescents with major depression: Impact of disease state and comorbid anxiety disorder

Clin Neurophysiol.

Feldmann L, Piechaczek CE, Grünewald BD, Pehl V, Bartling J, Frey M, Schulte-Körne G, Greimel E

doi: 10.1016/j.clinph.2018.09.028.

Evaluation of Progressive Visual Dysfunction and Retinal Degeneration in Patients With Parkinson's Disease

Invest Ophthalmol Vis Sci.

Satue M, Rodrigo MJ, Obis J, Vilades E, Gracia H, Otin S, Fuertes MI, Alarcia R, Crespo JA, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E

doi: 10.1167/iovs.16-20460.

Parkinson’s Disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

J Neurol.

Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P

doi: 10.1007/s00415-

Anxiety and Depression

Moderating effect of comorbid anxiety disorders on treatment outcome in a randomized controlled psychotherapy trial in early-onset persistently depressed outpatients

Depress Anxiety.

Assmann N, Schramm E, Kriston L, Hautzinger M, Härter M, Schweiger U, Klein JP

doi: 10.1002/da.22839.

Related content

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease

Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Resting frontal EEG asymmetry in adolescents with major depression: Impact of disease state and comorbid anxiety disorder

Evaluation of Progressive Visual Dysfunction and Retinal Degeneration in Patients With Parkinson's Disease

Is Parkinson's disease a chronic low-grade inflammatory bowel disease?

Moderating effect of comorbid anxiety disorders on treatment outcome in a randomized controlled psychotherapy trial in early-onset persistently depressed outpatients